Presenters review how genomic, trasncriptomic, and other omic technologies can help us understand the causes and inform treatments for MASLD. Experts elaborate on integrative multiomic analyses, genetic subtyping and risk stratification, phenotypic clustering, microbiome analyses, and metabolic and genetic metabolomic profiles as they relate to MASLD.